Accure Therapeutics awarded a total of $1.6M in grants from The Michael J. Fox Foundation and Fonds National de Recherche de Luxembourg to bring first-in-class drug for Parkinson’s disease to clinical trials
Accure Therapeutics partner Oculis reached positive phase 2 results for lead neuroprotective therapy
Accure Therapeutics awarded €1 million from Spanish government to evaluate ACT-03 for post-traumatic epilepsy
Accure Therapeutics appoints Dr Philippe Monteyne as Chairman of the Board of Directors
The Gelatinase Inhibitor ACT-03 Reduces Gliosis in the Rapid Kindling Rat Model of Epilepsy, and Attenuates Inflammation and Loss of Barrier Integrity In Vitro
L’agencia per a la Competitivitat de l’Empresa, ACCIÓ, en data 1 de març de 2018 ha atorgat a Iproteos (Accure Therapeutics) la concessió d’una subvenció per les seves aportacions a les teràpies pel Parkinson
Accure Therapeutics presented at EAN the improvement of neurodegeneration with ACT-02 in a preclinical study of Parkinson’s disease
Oculis Strengthens Leading Ophthalmology Pipeline by In-Licensing Neuroprotective Drug Candidate for Glaucoma from Accure Therapeutics
Conferencia online: “La esclerosis múltiple en los próximos 15 años”
Accure Therapeutics presented at ECTRIMS four communications reporting the progress of ACT-01 neuroprotective therapy for Multiple Sclerosis
Webinars on Neuroprotection for Brain Diseases Program
Accure Therapeutics enrols first patient in phase II clinical trial on acute optic neuritis with lead candidate ACT-01
